A Chrysin Derivative Suppresses Skin Cancer Growth by Inhibiting Cyclin-dependent Kinases
Author
Liu, Haidan
Liu, Kangdong
Huang, Zunnan
Park, Chan-Mi
Thimmegowda, N. R.
Jang, Jae-Hyuk
Ryoo, In-Ja
He, Long
Kim, Sun-Ok
Oi, Naomi
Lee, Ki Won
Soung, Nak-Kyun
Bode, Ann M.
Yang, Yifeng
Zhou, Xinmin
Erikson, Raymond L.
Ahn, Jong-Seog
Hwang, Joonsung
Kim, Kyoon Eon
Dong, Zigang
Kim, Bo-Yeon
Published Version
https://doi.org/10.1074/jbc.M113.464669Metadata
Show full item recordCitation
Liu, Haidan, Kangdong Liu, Zunnan Huang, Chan-Mi Park, N. R. Thimmegowda, Jae-Hyuk Jang, In-Ja Ryoo, et al. 2013. “A Chrysin Derivative Suppresses Skin Cancer Growth by Inhibiting Cyclin-Dependent Kinases.” Journal of Biological Chemistry288 (36): 25924–37. https://doi.org/10.1074/jbc.M113.464669.Abstract
Chrysin (5,7-dihydroxyflavone), a natural flavonoid widely distributed in plants, reportedly has chemopreventive properties against various cancers. However, the anticancer activity of chrysin observed in in vivo studies has been disappointing. Here, we report that a chrysin derivative, referred to as compound 69407, more strongly inhibited EGF-induced neoplastic transformation of JB6 P+ cells compared with chrysin. It attenuated cell cycle progression of EGF-stimulated cells at the G1 phase and inhibited the G1/S transition. It caused loss of retinoblastoma phosphorylation at both Ser-795 and Ser-807/811, the preferred sites phosphorylated by Cdk4/6 and Cdk2, respectively. It also suppressed anchorage-dependent and -independent growth of A431 human epidermoid carcinoma cells. Compound 69407 reduced tumor growth in the A431 mouse xenograft model and retinoblastoma phosphorylation at Ser795 and Ser-807/811. Immunoprecipitation kinase assay results showed that compound 69407 attenuated endogenous Cdk4 and Cdk2 kinase activities in EGF-stimulated JB6 P+ cells. Pulldown and in vitro kinase assay results indicated that compound 69407 directly binds with Cdk2 and Cdk4 in an ATP-independent manner and inhibited their kinase activities. A binding model between compound 69407 and a crystal structure of Cdk2 predicted that compound 69407 was located inside the Cdk2 allosteric binding site. The binding was further verified by a point mutation binding assay. Overall results indicated that compound 69407 is an ATP-noncompetitive cyclin-dependent kinase inhibitor with anti-tumor effects, which acts by binding inside the Cdk2 allosteric pocket. This study provides new insights for creating a general pharmacophore model to design and develop novel ATP-noncompetitive agents with chemopreventive or chemotherapeutic potency.Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41534464
Collections
- FAS Scholarly Articles [18296]
Contact administrator regarding this item (to report mistakes or request changes)